Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Background: The prolonged circulation time of nanoparticles in the blood is a prerequisite to
realize a controlled and targeted (passive or active targeting) release of the encapsulated …

The use of bronchodilators is one of the key elements in the treatment of chronic obstructive
pulmonary disease (COPD), although there is often limited reversibility of airflow obstruction …

Inhaled pharmaceuticals are formulated and delivered differently according to the
therapeutic indication. However, specific device-formulation coupling is often fickle, and new …

Introduction: The inhaled route has many advantages, but requires the patient to use, and to
master the use of, an inhaler device. Poor inhaler technique and non-adherence to therapy …

Enhanced therapeutics are drug products derived from existing generic drugs that provide
additional benefits to the patients and the healthcare system. Enhanced therapeutics are …

Introduction: Nebulizers are a common device choice for use when developing a new drug
product, but the range of nebulizer devices available can make it difficult to select the right …

The pulmonary route of administration is used to treat respiratory and systemic diseases and
has gained increasing importance in the field of drug delivery due to its unique advantages …

Pulmonary drug delivery (PDD) with dry powder inhaler (DPI) has rapidly developed for the
treatment of local and systemic diseases, which targets the delivery of fine drug particles into …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) …